A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions

Inclusion criteria

• healthy male and female subjects of Caucasian race
• able to read, to write and to fully understand German language
• having given voluntary written informed consent before first invasive screening examination procedure
• aged 18 to 45 years, inclusive
• BMI of 18 - 28 kg/m2
• good health as determined by medical history, physical examination, vital signs, electrocardiogram (ECG, serum/urine biochemistry and hematology)

Exclusion criteria

• clinically relevant allergy (except for untreated, asymptomatic, seasonal allergies at time of dosing) drug hypersensitivity
• known hypersensitivity to one of the IMP substances
• severe digestive disorder or surgery of the digestive tract (except for appen¬dectomy)
• clinically relevant renal disorders (albuminuria, chronic infections)
• clinically relevant hepatic disorders
• clinically relevant respiratory disorders
• clinically relevant cardiovascular disorders, especially any history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular ectopics, or a history of additional risk factors for torsades de pointes (TdP) (e.g. heart failure, hypokalemia, congenital long QT-syndrome)
• diabetes mellitus and thyroid dysfunction or other endocrine disorders
• malignancy
• substance abuse or addiction (alcohol, illicit drugs) in the past 3 years
• neurologic or psychiatric illness
• known predisposition to bleeding (e.g. active peptic ulceration, recent (within 6 month) haemorrhagic stroke, surgery within the previous three months, proliferative diabetic retinopathy, poorly controlled hypertension)